PLX51107

Overview

PLX51107 is a potent and selective BET inhibitor, with K d s of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 ( K d , in the 100 nM range).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Bladder Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-111422
• CAS No.: 1627929-55-8
• Molecular Formula: C26H22N4O3
• Molecular Weight: 438.48
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (5.70 mM); Clear solution
• Availability: In-stock

Source

Original product source